Bioheart Announces Mike Tomas Appointed CEO -- Mike Tomas has been appointed President and Chief Executive Officer and member of the Board of Directors effective immediately. Dr. Karl Groth, who has been Bioheart's President and Chief Executive Officer, will retain his position as Chairman of the Board of Directors.
June 23, 2010
Bioheart Announces Cell Therapies Program in the Middle East for Congestive Heart Failure and Peripheral Arterial Disease Patients -- The company has commenced work in Jordan on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). The first patient is expected to receive treatment in July.
May 28, 2010
Bioheart Commenced Successful Regenerative Stem Cell Treatments with Latin American Patients Having Congestive Heart Failure
April 14, 2010
Bioheart’s Chief Scientific and Technology Officer Increases His Bioheart Stake -- Bioheart's Chief Scientific and Technology Officer, converted a loan he had made to Bioheart and the loan's related interest, constituting together over $2 million, into restricted common shares and warrants through Bioheart's Private Investment in Public Equity.
April 1, 2010
Former Director Increases His Bioheart Stake -- former Board Member, vascular surgeon Dr. Sam Ahn increased his stake in the Company.
March 16, 2010
Bioheart Directors Take Further Stake in Company -- Bioheart, Inc., announced today that four members of its Board of Directors have added to their ownership positions
Mar 9, 2010
Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients
February 5, 2010
Bioheart Launches First US FDA Approved Clinical Trial that Tests Gene-Modified Stem Cell Therapy in Patients with Congestive Heart Failure -- New-Medical.net
Feb 4, 2010
Bioheart, Inc. Launches First US FDA Approved Clinical Trial that TestsGene-Modified Stem Cell Therapy In Patients With Congestive Heart Failure -- Reuters
Feb 4, 2010
Bioheart signs distribution agreements to market Home Heart Failure Monitoring Systems in U.S.
January 6, 2010
Bioheart Inc. inked a distribution agreement with Alamo Scientific Inc. to sell the company’s home heart failure monitoring system
January 6, 2010
Bioheart Inks Deals with Distributors to Introduce Home Heart Failure Monitoring Systems Throughout the U.S.
January 05, 2010
Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue -- Bioheart, Inc. offers yet another medical breakthrough with the next-level stem cell treatment for critical limb ischemia patients. The stem cells aid in promoting angiogenesis
January 4, 2010
Bioheart makes breakthrough in stem cell treatment for critical limb ischemia -- The Bioheart adipose derived stem cells treatment "ASCs Treatment"
December 22, 2009
Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue -- A large quantity of stem cells can be obtained from a patient's fat (adipose) tissue without pain and other side effects, quickly and cheaply. Adipose stem cells are capable of promoting blood
Dec. 21, 2009
Bioheart Elects Lee Jones to Its Board of Directors
Nov 11, 2009
Recovery of Damaged Heart Possible Through Stem Cells Therapy
Nov 11, 2009
Bioheart Makes Breakthrough in Cardiovascular Therapy with Stem Cells Obtained from Fat Tissue
Sept 30, 2009
Bioheart Inc. Announces Positive Results in the MARVEL Phase II/III Clinical Trial
Sept 18, 2009